Show the full website
Medicin & Biotek
Medico & Rehab
Laboratorie & Diagnostik
Sygdom & Sundhed
Top picks in English
Spinout specialists from Saniona start third company: "We have a very innovative research group"
Chairman becomes major investor in company that wants to prevent Alzheimer's disease using light therapy
Billion-dollar fund will boost corona vaccine research potential
Entrepreneurs raise DKK 10 million to help sperm quality test penetrate lucrative US market
New Chemometec CEO is on the hunt for growth - starts new antibodies effort
Nine companies win first joint Scandinavian call for medicine tenders
Jesper Høiland made a decision, and share prices fell by 17 percent: "That's just part of taking responsibility"
Lundbeck increases research and development budget
Family owners want to make pharmaceutical company global
WS Audiology CEO expects profit this year after billion-kroner deficit in 2019
Purchases and shake-ups in Asia have made Lundbeck larger than ever - and more employees are on the way
Zealand Pharma wants to buy access to the US market through bankrupt firm
Vaccine company aims to win race against industry giants to hit the jackpot with Coronavirus
Pharmacosmos bets on new subsidiary for product launch in USA
Lundbeck has potential name for migraine drug: Vyepti
Share issue gives Orphazyme breakthrough with US investors
Coloplast growth in danger: "There is no doubt that Coronavirus will impact the second quarter"
Novo gave 71 percent discounts last year: "We gave away suitcases with USD 20 billion in cash"
Closed Chinese factories provide 40 percent of GN's production: "Of course it is affecting our business"
GN lays out new strategy to continue market domination: wants to understand customers best
Novo Nordisk sales troops are ready: "We are going all-in on Rybelsus and all-in on Ozempic"
Bavarian Nordic will extend brand new factory to make space for new purchase
Hellmann:The transformation of ALK is ahead of schedule and will be cheaper than expected
Coronavirus brings Demant's operations in China to a standstill: Expensive in the short-term, but not a big worry
AJ Vaccines shifts focus after heavy investments in production: Wants to compete for market shares